Salix slides on expected delay for Xifaxan

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) fell $9.84 (24%) to $31.61 on Thursday after saying it expects to receive a complete response letter for Xifaxan rifaximin 550 mg tablets based on a telephone conversation with the agency about the irritable bowel syndrome (IBS) candidate. Salix attributed the expected setback to FDA's "newly expressed need for retreatment information;" however, the company said it only has limited information about the letter's content at this time. The sNDA is under review to treat non-constipation IBS and IBS-related bloating, with a PDUFA date of March 7. ...